STIMULAX 试验:刺激性与渗透性泻药对结直肠术后胃肠功能恢复的影响
单中心开放标签随机对照试验纳入 170 例择期结直肠手术患者,评估在加速康复方案基础上加用多模式泻药(Coloxyl®加番泻叶、聚乙二醇,右半手术加磷酸钠灌肠)对胃肠功能恢复的影响。结果显示 STIMULAX 组胃肠功能复合终点 GI-2 中位时间缩短 1 天,术后持续性肠梗阻发生率降低,住院时间和 30 天并发症无差异。
要点
- 择期结直肠术后常规加用多模式泻药可缩短胃肠功能恢复时间约 1 天。
- 多模式泻药使术后持续性肠梗阻发生率从 38% 降至 22%。
- 住院时间与 30 天并发症(含吻合口漏)未见差异。
核心结论
- 择期结直肠术后常规使用多模式泻药可更早恢复胃肠功能并降低持续性肠梗阻发生率。
研究设计与样本
- 单中心、平行、开放标签随机对照试验,2018 年 8 月至 2020 年 5 月在 Royal Adelaide Hospital 招募择期结直肠切除或造口形成/还纳的成人患者,共 170 例,每组 85 例,按意向治疗分析。
主要发现
- STIMULAX 组中位 GI-2 为 2 天(i.q.r. 1.5–4),对照组为 3 天(2–5.5),差值 95%CI −1 至 0 天,P=0.029。
- STIMULAX 组持续性肠梗阻发生率为 22%,对照组为 38%,相对风险降低 42%,P=0.030。
- 两组住院时间和 30 天术后并发症(包括吻合口漏)无差异。
关键数值与推荐
- STIMULAX 组口服 Coloxyl®加番泻叶和聚乙二醇,右半手术额外使用磷酸钠灌肠;对照组接受标准加速康复术后护理。
- 主要结局 GI-2 定义为从手术至首次排便且耐受固体饮食 24 小时无呕吐的间隔时间。
临床怎么用
- 在加速康复方案基础上,可考虑对择期结直肠手术患者常规术后使用多模式泻药以促进胃肠功能恢复并减少持续性肠梗阻。
局限性
- 单中心、开放标签设计可能引入偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recovery of gastrointestinal (GI) function is often delayed after colorectal surgery. Enhanced recovery protocols (ERPs) recommend routine laxative use, but evidence of benefit is unclear. This study aimed to investigate whether the addition of multimodal laxatives to an ERP improves return of GI function in patients undergoing colorectal surgery. METHODS: This was a single-centre, parallel, open-label RCT. All adult patients undergoing elective colorectal resection or having stoma formation or reversal at the Royal Adelaide Hospital between August 2018 and May 2020 were recruited into the study. The STIMULAX group received oral Coloxyl® with senna and macrogol, with a sodium phosphate enema in addition for right-sided operations. The control group received standard ERP postoperative care. The primary outcome was GI-2, a validated composite measure defined as the interval from surgery until first passage of stool and tolerance of solid intake for 24 h in the absence of vomiting. Secondary outcomes were the incidence of prolonged postoperative ileus (POI), duration of hospital stay, and postoperative complications. The analysis was performed on an intention-to-treat basis. RESULTS: Of a total of 170 participants, 85 were randomized to each group. Median GI-2 was 1 day shorter in the STIMULAX compared with the control group (median 2 (i.q.r. 1.5-4) versus 3 (2-5.5) days; 95 per cent c.i. -1 to 0 days; P = 0.029). The incidence of prolonged POI was lower in the STIMULAX group (22 versus 38 per cent; relative risk reduction 42 per cent; P = 0.030). There was no difference in duration of hospital day or 30-day postoperative complications (including anastomotic leak) between the STIMULAX and control groups. CONCLUSION: Routine postoperative use of multimodal laxatives after elective colorectal surgery results in earlier recovery of gastrointestinal function and reduces the incidence of prolonged POI. Registration number: ACTRN12618001261202 (www.anzctr.org.au).
引用
- Dudi-Venkata NN, Kroon HM, Bedrikovetski S, et al. Impact of STIMUlant and osmotic LAXatives (STIMULAX trial) on gastrointestinal recovery after colorectal surgery: randomized clinical trial. Br J Surg. 2021. PMID: 34136900. doi:10.1093/bjs/znab140
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。